News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Swiss Back Two-in-one GlaxoSmithKline Prostate Drug Duodart
March 22, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- A two-in-one prostate drug from GlaxoSmithKline (GSK.L) has won approval in Switzerland, its first European market, the British-based drugmaker said on Monday.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
GlaxoSmithKline
MORE ON THIS TOPIC
Podcast
China Crackdown, UK Exit, Novo Layoffs, Adcomm Flip Flop, More
September 17, 2025
·
2 min read
·
Heather McKenzie
Obesity
Novo, Lilly Jostle For Market Lead in Obesity With New Regulatory Efforts
September 16, 2025
·
2 min read
·
Tristan Manalac
Vaccines
Kennedy Names New ACIP Members as Panel Quiets COVID-19 Vaccine Developers Ahead of Meeting
September 16, 2025
·
2 min read
·
Tristan Manalac
Manufacturing
Trump’s Reshoring Drive Raises Questions About Supply Resilience
September 16, 2025
·
4 min read
·
Nick Paul Taylor